COSCIENS Biopharma Inc. CSCIF
6.10
0.62
11.31%
as of 25 Sep
- Market cap
- $8.6M
- P/E
- 1.0×
Follow CSCIF
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| 59.74% | 31.84% | (121.84%) | (118.80%) |
+8 more TTM periods Free account |
|
| 28.24% | 16.22% | (36.66%) | (44.08%) | ||
ROIC |
(40.56%) | (51.58%) | 0.00% | 0.00% | |
Return on Tangible Assets |
40.44% | 23.91% | (58.54%) | (75.50%) | |
Average Days of Receivables |
99.19 | 90.99 | 61.39 | 68.05 | |
Free Cash Flow per Share |
(3.36) | (8.23) | (8.47) | (10.36) | |
Free Cash Flow |
(3.52) | (8.61) | (8.93) | (10.97) | |
Capital Expenditures |
0.20 | 0.16 | (0.46) | (0.96) | |
Piotroski F-Score |
5.00 | 4.00 | 2.00 | 4.00 | |
| Other line items | |||||
Cash ROIC |
(18.51%) | (43.15%) | (76.00%) | (73.52%) | |
Accounts Receivable Turnover |
3.39 | 4.15 | 4.02 | 4.76 | |
Accounts Payable Turnover |
2.42 | 1.75 | 1.47 | 1.42 | |
Inventory Turnover |
3.36 | 2.77 | 2.43 | 1.90 | |
Average Days of Payables |
62.60 | 68.59 | 141.68 | 147.61 | |
Days of Inventory on Hand |
75.03 | 81.40 | 98.34 | 133.29 | |
Tax Rate |
0.00 | 0.00 | 0.09 | 0.00 | |
Research and Development Expense of Revenue |
26.69% | 32.87% | 39.34% | 50.75% | |
Selling, General and Administrative Expense of Revenue |
90.04% | 110.99% | 134.20% | 111.43% | |
Share Based Compensation of Revenue |
0.78% | (0.21%) | (0.16%) | (1.05%) | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
(0.57) | (2.16) | 0.82 | 0.67 | |
Depreciation/Fixed assets |
0.14 | 0.12 | 0.11 | 0.04 | |
Capex/Depreciation |
0.16 | 0.14 | (0.43) | (2.66) | |
Revenue per Share |
8.33 | 7.64 | 7.11 | 8.13 | |
Operating CF per Share |
(3.56) | (8.38) | (8.03) | (9.45) | |
Capex per Share |
0.19 | 0.15 | (0.44) | (0.91) | |
Capex to Sales |
(0.02) | (0.02) | 0.06 | 0.11 | |
Net Profit Margin |
75.11% | 50.68% | (138.14%) | (173.14%) |
Columns are period end dates